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Abstract 
An autocrine driven upregulation of the Hedgehog (Hh) signaling pathway has been described in 
malignant pleural mesothelioma (MPM), in which the ligand, desert hedgehog (DHH), was produced 
from tumor cells. However, our investigation revealed that the Hh pathway is activated in both tumor 
and stroma of MPM tumor specimens and an orthotopic immunocompetent rat MPM model. This was 
demonstrated by positive immunohistochemical staining of Glioma associated oncogene 1 (GLI1) and 
Patched1 (PTCH1) in both tumor and stromal fractions.  DHH was predominantly expressed in the 
tumor fractions. To further investigate the role of the Hh pathway in MPM stroma, we antagonized Hh 
signaling in the rat model of MPM using a Hh antagonist, vismodegib, (100 mg/kg peroral). Daily 
treatment with vismodegib efficiently downregulated Hh target genes, Gli1, Hedgehog Interacting 
Protein (Hhip) and Ptch1, and caused a significant reduction of tumor volume, and tumor growth 
delay.  Immunohistochemical analyses revealed that vismodegib treatment primarily down regulated 
GLI1 and HHIP in the stromal compartment along with a reduced expression of previously described 
fibroblast Hh responsive genes such as Fibronectin (Fn1) and Vegf. Primary cells isolated from the rat 
model cultured in 3%O2 continued to express Dhh but did not respond to vismodegib in 
vitro. However, culture supernatant from these cells stimulated Gli1, Ptch1, and Fn1 expression in 
mouse embryonic fibroblasts which was suppressed by vismodegib. Our study provides new evidence 
regarding the role of Hh signaling in MPM stroma in the maintenance of tumor growth, emphasizing 
Hh signaling as a treatment target for MPM.  
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Introduction 
Malignant Pleural Mesothelioma (MPM), an aggressive cancer most often caused by asbestos 
exposure, is still a public health concern. MPM arises from malignant transformation of the mesothelial 
cell layer lining the pleural cavity (1). About 80% of MPM cases are related to asbestos exposure, 
further causes are other environmental exposures and genetic predisposition. Incidence rates in 
Western European nations and Australia are still rising with expected peak around 2020 and beyond 
(2) due to long disease latency (3). The prognosis of MPM remains poor. Intensive multimodal 
regimen combining chemotherapy, surgery and radiotherapy contributed to a median overall survival 
of 24 months (4). Currently, other treatment options including molecular targeted therapy as well as 
immunotherapy are being a focus of interest. 
Recent findings of the activated Hedgehog (Hh) signaling pathway in MPM have underlined its 
role as a target for MPM treatment (5-7). The Hh pathway is one of the crucial stem cell signaling 
pathways that regulate embryonic development and adult tissue repair (8). In the absence of Hh ligand 
binding, the receptor Patched (PTCH1) represses the transmembrane G protein-coupled receptor 
Smoothened (SMO). Binding of ligands (Sonic hedgehog (SHH), Indian hedgehog (IHH) and Desert 
hedgehog (DHH)) to PTCH1 unleashes SMO to induce Hh pathway activation via an intracellular 
signaling cascade. The transcription factors glioma-associated oncogenes 1-3 (GLI1, GLI2 and GLI3) 
convey the cytoplasmic signal and induce transcription of pro-proliferative and anti-apoptotic target 
genes, such as GLI1, PTCH1, Hedgehog interacting protein (HHIP), CyclinD1 or BCL2 (8) depending 
on cell type and situation. Constitutive pathway activation resulting from mutations of pathway 
components is frequently detected in sporadic basal cell carcinoma (BCC) and medulloblastoma (MB) 
(9, 10). Furthermore, aberrant up-regulation of Hh pathway in ligand dependent (paracrine or 
autocrine) manner has been described in hematologic malignancies and several solid tumors (11). 
Studies in colon and pancreatic adenocarcinoma demonstrated the paracrine activation of Hh 
signaling (12, 13). In these studies, human tumor cells cultured in vitro did not respond to a SMO 
antagonist. In contrast, the treatment with the SMO antagonist in subcutaneous tumor xenograft 
resulted in delayed tumor growth. Gene expression analyses suggested that only murine stroma but 
not tumor epithelium could respond to SMO antagonist explaining the lack of response in vitro (12, 
13). Co-culture experiments further showed the paracrine activation of Hh signaling in lung and 
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prostate cancer (14, 15). These highlight the importance of Hh signaling in tumor and thus serves as a 
rational for a treatment targeting cancer (11). 
In MPM, increased SHH and GLI1 mRNA expression was detected in tumor tissues compared 
to normal mesothelium (5). High GLI1 expression (5) and high SMO and SHH protein levels (6) were 
associated with poor survival of MPM patients. Recent data from The Cancer Genome Atlas (TCGA) 
demonstrated that the Hh pathway is among the top 10 most deregulated pathways in MPM 
[Reviewed in (16)]. Altogether, these data underline the importance of the Hh pathway in MPM. 
Nevertheless, mutations of Hh pathway components in MPM were reported to be relatively rare (17). 
So far, up-regulation of the Hh signaling in MPM has been demonstrated in ligand dependent 
autocrine manner, interestingly only mediated by DHH in the primary culture in 3% O2 without serum 
(5). It is important to note that 2 out of 6 MPM primary cells employed in that study were not 
responsive to a SMO antagonist (5) suggesting a possible role of paracrine activation in MPM. Indeed, 
here we provide new evidence regarding paracrine Hh activation in MPM. Using an immunocompetent 
orthotopic rat MPM model, we demonstrated that Hh pathway activation in stroma plays a role in the 
maintenance of tumor growth. 
 
Materials and Methods 
Patient tissue samples  
Eight diagnostic MPM tumor specimens and two tissue micro arrays from 138 patients 
collected between 1999-2009 were employed. The study was approved by the institutional review 
board (ethical approval numbers: StV 29-2009 and EK-ZH 2012-0094) and all patients received and 
signed a written inform consent. Formalin-fixed paraffin-embedded tissues were cut into 3 μm thick 
slices and processed for immunohistochemistry and scored semi-quantitatively as described below. 
Cell culture  
Rat mesothelioma cell line IL45 was originally produced in rat exposed intraperitoneally to 
asbestos (18). IL45 expressing luciferase (IL45-luc) was generated by us in 2011 by stable 
transfection of IL45 with luciferase expressing vector (19). Both IL45 and IL45-luc were maintained in 
RPMI1640 containing 1mM sodium pyruvate, Penicillin/Streptomycin (P/S), 200 μg/ml Geneticin 
(G418) and 10% fetal bovine serum (FBS) at 37°C with 5% CO2. NIH3T3, employed for Hh activity 
assay as described in the previous publication (5), were maintained in RPMI (ATCC modification) 
supplemented with 10% FBS and 1% P/S at 37° C, 5% CO2. Rat and mouse cell lines employed in 
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this study were tested for the absence of Mycoplasma but were not authenticated by us. Primary 
culture of tumors was performed using the previously described method ((6); and maintained in 
medium w/o serum (Dulbecco's Modified Eagle's Media:F12, 0.4 μg/mL hydrocortisone, 10 ng/mL rat-
EGF, 20 ng/mL rat-basic fibroblast growth factor, 10 μg/mL insulin, 5.5 μg/mL transferrin, 6.7 μg/mL 
selenium, 1 mmol/L sodium pyruvate, 100 μmol/L β-mercaptoethanol, nonessential amino acids and 
30% own conditioned medium) at 37°C, 5%O2, 3%O2.   
In vitro treatment with vismodegib, viability and colony formation assay 
Vismodegib was prepared in DMSO and stored at -20°C. Working dilutions were freshly 
prepared in culture medium containing 0.5% FBS. A viability assay of the IL45-luc monolayer cells was 
performed using Methylthiazolyldiphenyl-tetrazolium bromide (MTT) after 72 hour treatment. Primary 
IL45-luc derived from tumors maintained in 3% O2 without serum formed clumps and spheres. For this 
reason, the acid phosphatase (APH) assay using ImmunoPure p-nitrophenyl phosphate substrate (20) 
was employed to measure their viability. Colony formation assay was performed in 0.5% FBS. Cells 
were treated with vismodegib for 10 days, and stained with crystal violet and analyzed under a light 
microscope where colonies with ≥ 5 cells were counted. All results were confirmed in at least 3 
independent experiments. 
NIH3T3 treatment with cell culture supernatant 
Supernatant from primary culture of rat tumors were harvested freshly, after centrifugation at 
400 g for 5 minutes. Supernatant from a primary human MPM culture was harvested and kept at 4ºC 
until used. NIH3T3 cells were seeded in a 6 well plate at 900,000 cells/well in the complete medium. 
After overnight incubation at atmospheric oxygen level, the medium were then replaced by 
supernatant from primary culture mixed with 0.05% DMSO or vismodegib. SMO agonist (SAG: Abcam; 
Ab142160) was employed as a positive control. SAG powder was dissolved in DMSO and stored at -
20ºC. Working dilution of SAG was freshly prepared and added to culture medium used for rat primary 
culture. After receiving the treatment, NIH3T3 were incubated at 37°C, 5%CO2 and 3%O2. Cells were 
harvested at 72 hour later for RNA extraction. The results were confirmed by at least 2 independent 
experiments except for the treatment with human MPM supernatant where no material was available 
for the duplication. 
Orthotopic rat MPM model and treatment  
The experimental scheme is depicted in figure 3a. The animal experiment was authorized by 
the veterinary office of canton Zurich, Switzerland (112/2013). Male Fischer 344 rats (n=12, 200-250 
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grams; Harlan Laboratories, the Netherland) were housed according to the guideline for animal 
welfare. A sterile 50 µl of 500,000 IL45-luc cell suspension in Dulbecco’s Phosphate Buffered Saline 
(DPBS) was implanted underneath the parietal pleura using a surgical procedure as previously 
described (21). In order to start with the same tumor size, the treatment started when the tumor was 
first detectable by bioluminescence (Bli) (between 2-6 days after implantation). Vismodegib free base 
(LC laboratories, V-4050) was dissolved in 0.5% Methylcellulose/0.2% Tween (MCT) solution and 
sonicated. The drug suspension was freshly prepared and administered once daily for 6 days by oral 
gavage at a dosage of 100 mg/kg (22). Control animals received only MCT. Once the treatment 
started, Bli was performed every second day until day 6. Magnetic resonance imaging (MRI) was 
performed after Bli measurement at day 6 prior to euthanasia. Macroscopic tumor volume was 
measured at autopsy using the ellipsoid volume formula V= 4/3 π * a/2 * b/2 * c/2 (a=length, b=width, 
c=thickness measured on H&E sections). 
Tumor imaging  
MRI was performed using a 4.7 Tesla small animal MR scanner equipped with a 1H whole-
body rat coil (Bruker 4.7-T PharmaScan 47/16 US). MR data sets were acquired applying T2-weighted 
fast spin-echo sequences in transverse/sagittal/coronal orientation (repetition time TR 3500 ms, echo 
time TE 45 ms). The tumor volume (mm3) was quantified blindly with Image J software (NIH, MD) by 2 
observers as we described previously (23). 
 Bli was performed in the imaging chamber of the IVIS200 (Caliper Life Sciences, Inc., MA, 
USA). Prior to the imaging procedure, rats were injected with 150 mg/kg body weight Xenolight D-
Luciferin –K+ salt (Perkin Elmer, 122796; dissolved in sterile DPBS). Bli measurement was recorded 
over 30 minutes with the exposure time of 60 seconds. When the maximum Bli signal was reached (in 
about 15-25 minutes), region of tumor was measured for Bli signal intensity (total flux; photon/second). 
RNA extraction and quantitative real time PCR 
RNA extraction was performed using Trizol® reagent (Ambion®, 15596-018) according to 
manufacturer´s instructions. 500 ng of total RNA was used for cDNA synthesis using RT2 first strand 
kit (Qiagen, 205311). Quantitative real time PCR was performed using Power SYBR® green PCR 
mastermix (Applied biosystems®, 4368577). Primers are listed in the supplementary table 1 or were 
previously described (24, 25). The reaction was performed in triplicate and normalized with a loading 
control, Histone H3 for rat cells and Beta actin (Acbt) for mouse cells (26). Relative quantitation (RQ) 
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of gene expression was calculated using the 2-∆∆Ct method. For in vivo samples, the following relative 
quantitation was applied RQ=2-(Ct,target-Ct,H3)/(average Ct,target-Ct,H3 of control group).  
Tissue processing and immunohistochemistry 
Tumor tissues were collected and immediately fixed in formalin. They were de-calcified in 
neutral EDTA pH 7.0 for 2-4 weeks before paraffin embedding. Tissues were cut into 3 μm slices and 
rehydrated through series of graded alcohol followed by immunohistochemistry using the following 
antibodies: GLI1 (Santa Cruz, H-300), Fibronectin (Abcam, ab6328), DHH (Santa Cruz, H-19), PTCH1 
(Aviva Systems Biology, ARP44249_P050), HHIP (Santa Cruz , H-280), Ki-67 (Cell Marque, 
CMC27531021), phospho-histone H3 (ser10) (Cell Signaling, #9701).  
GLI1 and DHH antigen retrieval was achieved by 20 minutes microwave (700 watt) cooking in sodium 
citrate buffer pH 6.0. After overnight incubation with primary antibodies at 4°C, the secondary antibody 
was applied followed by Vectastain ABC Reagent (Vector laboratories). DAB chromogen (Dako) was 
applied for visualization of the signals and counterstained with haematoxylin. PTCH1 and HHIP were 
stained with Dako Autostainer Link48 Instrument (Dako Denmark A/S). Antigen retrieval for PTCH1 
was performed using target retrieval solution high pH (Dako, K8004, 20 min, 97°C). For HHIP, target 
retrieval solution low pH (Dako, K8005; 20 min, 97°C) was employed for rat tissues and target retrieval 
solution high pH (Dako, K8004; 20 min, 97°C) was employed for human tissues. The visualization 
system consisted of the Dako EnVision™ Rabbit/HRP/DAB system and haematoxylin as counterstain. 
TUNEL staining was conducted on the Leica-bond RX automater using digoxigenein labelled dUTP 
(Roche, 11570013910) and terminal deoxynucleotidyl transferase (Promega, M1875) after enzymatic 
retrieval (Sophistolab AG, Muttenz, Switzerland). 
Quantitation of immunohistochemistry  
Images were captured with a light microscope (Leica DM6000). H-scoring system was applied 
to semi-quantitatively quantify protein expression by 3 observers (K.B, M.M and B.V.). Staining 
intensity was scored 0-3 (negative-strong). Staining frequency was set as 0.1 (<10% positive cells), 
0.5 (10-50% positive cells), 1 (>50% positive cells). The H-score was the multiplication of intensity and 
frequency (range 0-3). Proliferation, mitotic and TUNEL positive indices were calculated by counting 
positive tumor nuclei per total tumor cells (at least 1000 total cells). 
Statistical analysis 
The differences between means were verified by unpaired two-sided t-tests using the 
GraphPad Prism software. A statistical significant difference was defined for P values ≤ 0.05. 
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Results 
Hh pathway is activated in tumor and in stroma of human MPM  
Eight MPM tumor specimens including 6 epithelioid, 1 biphasic and 1 sarcomatoid were analyzed for 
the expression of GLI1, DHH, PTCH1 and HHIP by immunohistochemistry (figure 1a). In addition two 
TMAs consisting of 138 patients (89 epithelioid, 41 biphasic and 8 sarcomatoid) were analyzed for 
GLI1 and DHH expression. GLI1 is expressed in both tumor and stromal fractions in all the samples 
assessed.  When comparing tumor and stroma, DHH, PTCH1 and HHIP expression is higher in the 
tumor fraction (figure 1a).  
Hh pathway is activated in tumor and in stroma of an orthotopic immunocompetent rat model 
of mesothelioma  
To investigate the role of Hh signaling in MPM stroma, we employed our previously described rat MPM 
model, generated by the implantation of a rat mesothelioma cell line, IL45-luc, underneath parietal 
pleura of immunocompetent rats (19). IL45-luc cells cultured in vitro in the presence of 10% FBS 
expressed high levels of Gli1, Ptch1 and Smo, however mRNA levels of all Hh ligands were very low- 
or undetectable. Interestingly, a robust increase of Dhh mRNA level was detected in in vivo tumor 
compared to in vitro cell culture (figure 2a). Expression levels of other Hh pathway components, Gli1, 
Gli2 and Gli3 were reduced in tumor derived from IL45-luc compared to in vitro. Hhip, Hh pathway 
target gene and its’ negative regulator, became detectable only in vivo (figure 2a). Primary cells 
isolated from IL45-luc derived tumors, cultured in 3%O2 without serum continued to express Dhh but 
expressed only low levels of Gli1 when compared with in vivo or IL45-luc cultured in the presence of 
10% FBS (figure 2a).   
Histological assessment of the orthotopic tumors revealed that tumor cells were surrounded by stroma 
including extracellular matrix (ECM)/lymphocytes/fibroblasts/blood vessels (figure 1b). Similar to 
human MPM, immunohistochemical analysis revealed predominant cytoplasmic localization of DHH in 
tumor cells but not in the stroma (S) whereas GLI1 was expressed in both tumor (T) and stroma 
fractions (figure 1b).  
The treatment with vismodegib did not downregulate Hh target genes in rat mesothelioma cell 
lines in vitro  
In terms of the sensitivity of these cell lines to Hh pathway inhibition in vitro, IL45 and IL45-luc 
responded to vismodegib at the same extent after 72 hours treatment (figure 2b). Growth inhibitory 
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effect was observed when using > 20 μM of vismodegib in both cell lines. This is in line with the 
literature reporting the effective concentration of vismodegib in vitro (7, 27). However, this 
concentration is much higher than the effective concentration reported for Hh responsive cell lines (13, 
27). Vismodegib could not suppress the expression of Hh target genes, Gli1and Ptch1 (figure 2c). We 
therefore employed colony formation assay to assess long term treatment effects (10 days). Although, 
a lower amount of vismodegib was required to inhibit colony formation of IL45 and IL45-luc cells 
(figure 2b) compared to short term treatment, this effective concentration was still higher than that 
required for Hh pathway inhibition (27). The unresponsiveness of IL45 and IL45-luc to vismodegib in 
terms of Hh target genes downregulation in vitro implied the lack of constitutive activation of Hh 
pathway in these cell lines.  
Treatment with vismodegib in vivo suppresses Hh signaling pathway mainly in stroma and 
induced significant reduction of tumor size and caused tumor growth delay 
Thus, we investigated the effects of the SMO antagonist, vismodegib, in the rat MPM model to further 
elaborate the role of Hh signaling. The experimental scheme is depicted in figure 3a. SMO antagonist, 
vismodegib was administered with the effective dosage applied in preclinical studies (22). Six days 
later, we observed that tumor volume measured by MRI was significantly reduced in the treated group 
compared to control (3 folds difference, p=0.03) (figure 3b). Consistently, significant reduction of 
macroscopic tumor volume (p=0.03) of the treated group was detected (figure 3d). Tumor growth 
monitored by Bli seems to be reduced in the treated group compared to control (see images in figure 
3e). Nevertheless the overall growth suppression was not statistically significant comparing control 
with treatment group, which may be in part due to the high standard deviation of the measurement 
(figure 3e).  
Robust reduction of mRNA levels of Gli1 Hhip and Ptch1 was observed in vivo after 
vismodegib treatment compared to control group (figure 4a). No significant change in the expression 
of Dhh, Gli2 and Gli3 was detected (figure 4a). The analysis in skin samples also showed strong down 
regulation of Gli1 (figure 4a), confirming the efficacy of vismodegib in the inhibition of the Hh pathway 
in this rat model. We further analyzed GLI1, PTCH1, HHIP and DHH expression by 
immunohistochemistry. Tumor fraction was clearly distinguishable based on large cell size, big nuclei, 
less spindeloid shape than fibroblast (figure 1b). Slightly reduced GLI1 expression in tumor cells was 
observed (figure 4b, 4c). Interestingly, we observed significant down regulation of GLI1 and HHIP in 
the stromal fraction of treated rats compared to controls (figure 4b, 4c). We did not detect any change 
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in PTCH1 expression on the protein level, may be because change in mRNA expression levels was 
small compared to GLI1 or HHIP (figure 4a). DHH expression levels remained unchanged in the 
treated rats (figure 4b).  
Vismodegib treatment reduces tumor cell proliferation rate but does not induce cell death 
Immunohistochemical analysis of Ki-67 and p-H3 (phospho-histone H3) indices was performed to 
assess proliferation and mitosis of tumor cells, respectively (figure 4d). Significant reduction of both Ki-
67 and p-H3 index in the treated group versus control was detected. TUNEL staining showed a very 
low percentage of dead cells without central necrosis in both control and treated tumors. No significant 
difference of TUNEL positivity was observed in the treated group compared to controls (figure 4d). 
Primary cells isolated from in vivo rat tumor model, cultured in 3%O2 without serum sustain the 
expression of Dhh but are not sensitive to vismodegib 
We previously observed that primary human MPM cells cultured in the physiological condition 
(in own conditioned medium with growth factors (see method) and 3%O2) could sustain stemness and 
DHH secretion (5). Therefore we isolated primary cells from the orthotopic rat tumors and cultured 
them in this condition. We indeed detected increased Dhh expression in primary cells cultured in 
3%O2 without serum compared to IL45-luc cultured in 10% serum and 20% O2 (figure 2a). This finding 
is consistent in primary cells isolated from 3 different animals (supplementary figure s1). We could not 
observe any correlation between Gli1 and Dhh expression in these cells (supplementary figure s1). 
The response of primary cells to vismodegib is identical to what we observed in IL45-luc cultured in 
serum (figure 5a). No difference in response to vismodegib was detected in cells isolated from control 
and vismodegib treated rats (figure 5a). No down regulation of Gli1 or Ptch1 was observed under this 
culture condition in response to SAG or vismodegib treatment (figure 5b, supplementary figure s2). 
The response of tumor cells to vismodegib (determined by IC50) did not correlate with the expression 
levels of Hh pathway components (Dhh, Smo, Ptch1, Gli1) (figure 5c).  
Treatment with vismodegib causes downregulation of Fibronectin, Vegf, and Lif expression, 
the previously described indirect Hh pathway targets in fibroblast  
We could not observe downregulation of other canonical Hh target genes namely CyclinD1 and Abcg2 
(figure 6a) (28, 29). Since in our model we observed that vismodegib treatment induced stronger GLI1 
down regulation in the stromal compared to the tumor compartment, we hypothesized that Hh pathway 
activation occurred primarily in a paracrine fashion. We therefore focused on the effects of vismodegib 
in stroma in order to understand the mechanisms leading to the reduced proliferation hence tumor 
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growth delay. Previous experiments suggest that antagonization of Hh pathway in fibroblasts reduces 
the production of extracellular matrix (ECM), cytokines and growth factors (13-15). Therefore we 
analyzed mRNA levels of the ECM molecules Fibronectin (Fn1) and Collagen (Col1a2). We did not 
detect differences in Collagen mRNA levels, may be due to the fact that the expression of collagen is 
too abundant (Col1a2 Ct~18 versus loading control Histone H3 Ct~22) to allow us to observe any 
difference. Nevertheless, we could detect a downregulation of Fn1 mRNA levels in the treated group 
(figure 6a). We further analyzed Fibronectin expression by immunohistochemistry and observed 
significantly reduced levels of Fibronectin in the treated group compared to controls (supplementary 
figure s3). Thus, one possibility is that the difference in tumor volume between control and vismodegib 
treated tumor might be in part due to reduced ECM content. In addition, Shh was shown to stimulate 
the secretion of VEGF and LIF (14) from fibroblasts. Indeed, in agreement with this finding, we 
observed here in vivo, a significant reduction on Vegf and Lif mRNA in the treated group compared to 
control (figure 6a).  
Culture supernatant of primary cells from in vivo rat tumors stimulated Gli1, Ptch1 and Fn1 
expression of NIH3T3 cells  
To confirm paracrine activation of Hh signaling between tumor cells and stroma, we employed in vitro 
assay using mouse embryonic fibroblast cells (NIH3T3). NIH3T3 were treated with the supernatant 
collected from primary cells derived from a rat tumor. 72 hours after the incubation with rat MPM 
supernatant in 3%O2, we observed a strong upregulation of Gli1 and Ptch1 in NIH3T3 cells which was 
reduced by the treatment with vismodegib. The treatment with 50 nM SAG induced slightly Gli1 
upregulation but not Ptch1 (figure 6b). This may be explained by the fact that Ptch1 expression is not 
strongly induced by the Hh pathway activation compared to Gli1 (eg. culture supernatant of primary 
cells induced 4 times Gli1 upregulation but only 1.8 Ptch1 upregulation (figure 6b)). NIH3T3 treated 
with SAG and rat supernatant showed upregulation of Fn1 which was suppressed by vismodegib 
treatment. Similar to the effect seen with the rat MPM cell culture supernatant, NIH3T3 treated with 
primary human MPM cell culture supernatant showed upregulation of Gli1, Ptch1 and Fn1 
(supplementary figure s4).    
 
Discussion 
In this study we provide new evidence regarding the importance of Hh signaling in MPM 
stroma in the maintenance of MPM tumor growth. The Hh pathway was activated in both tumor and 
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stroma of MPM human tissues and the orthotopic immunocompetent rat model. After continuous 
treatment with the SMO antagonist, vismodegib, in vivo, pronounced and significant down regulation of 
the well-known Hh target genes, GLI1 and HHIP was observed only in the stromal fraction. The tumor 
fraction was less responsive to vismodegib in vivo. This is further demonstrated in vitro where we 
could not see the effect of vismodegib in the down regulation of Gli1 in primary cells isolated from the 
rat MPM model. The outcomes of daily treatment with vismodegib targeting Hh pathway in the stroma 
included reduced tumor volume and suppressed tumor growth without inducing cell death. The 
treatment with vismodegib repressed indirect Hh responsive genes previously reported in fibroblasts 
i.e. Fn1, Vegf and Lif. Reduced levels of these factors may thus be responsible for tumor growth delay 
observed in this study  
We detected the expression of Hh pathway components GLI1, HHIP and PTCH1 in human 
MPM specimens in both tumor and stromal fractions. Hh ligand, DHH was weakly expressed and was 
predominantly localized in the tumor fraction. Similar to our finding, previous studies also showed that 
another Hh ligand detected in human MPM, SHH, is also weakly expressed in only 47% of patients 
(7). The similar pattern of GLI1, PTCH1, HHIP and DHH expression was observed in orthotopic 
immunocompetent rat mesothelioma model. IL45-luc cells that were implanted orthotopically in 
syngeneic rats started to express Dhh but not the other Hh ligands. Nevertheless, Gli1, Gli2 and Gli3 
expression levels were reduced in vivo. One most possible explanation is the presence of 10% fetal 
bovine serum (FBS) in in vitro culture medium. We observed that when the FBS was withdrawn from 
IL45-luc, Gli1 expression was strongly reduced (unpublished observations). The upregulation of Gli1 in 
the presence of FBS is presumably mediated by Hh independent mechanism as its expression could 
not be suppressed by the treatment with vismodegib. The expression of Dhh was still maintained when 
isolated and cultured without serum in 3%O2. This observation was also documented in primary 
culture of human MPM cells cultured in 3%O2 without serum in which DHH was the only ligand 
expressed (5). So far there is no obvious explanation and it remains to be elucidated why the primary 
culture and this in vivo MPM models upregulate only the expression of DHH but not other ligands.  
Target genes responding to Hh pathway stimulation have been shown to be dependent on cell 
type and context. Shh has been shown to indirectly induce angiogenesis in juvenile and adult mice by 
up-regulating angiogenic factors including Vegf (30). In this study it was also demonstrated in vitro that 
only fibroblasts could secrete VEGF upon Hh pathway stimulation. Another finding showed in vitro that 
lung fibroblasts upregulated LIF and VEGF expression when treated with cell culture supernatant of 
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lung cancer cell lines that secrete SHH (14).  In line with these studies, we also observed here, in vivo, 
down regulation of Lif and Vegf expression following Hh pathway suppression by vismodegib. In 
addition, cell culture supernatant of primary rat and human MPM cells could stimulate Gli1, Ptch1 and 
Fn1 expression in NIH3T3 when incubated at 3%O2, 37ºC for but not at atmospheric O2 level. Under 
this culture condition, we did not detect an increase in Lif and Vegf expression in NIH3T3 cells treated 
either with cell culture supernatant or SAG (unpublished observations). One possible reason is that the 
tested in vitro condition does not fully recapitulate in vivo tumor micro-environment. Although Fn1, Lif 
and Vegf can also be produced by some MPM cells, (31-33), it is not known whether these are Hh 
responsive genes in tumor. Based on our results being i) stroma was the main part affected by 
vismodegib ii) Fn1, Lif and Vegf have been so far described to be regulated by the Hh pathway only in 
fibroblast, we presume that the effects of vismodegib that we observed herein results primarily from 
the modulation of fibroblasts. Interestingly, Vegf promoters do not contain GLI1 binding consensus 
sequence (14). Thus, the effect of vismodegib on Vegf expression could mostly stem from indirect 
regulation. One mediator could be hypoxia as a study in pancreatic cancer demonstrated that SHH 
secreted from tumors stabilized HIF1α, a known transcription factor of VEGF, in pancreatic fibroblasts 
(34).  
In vitro, high concentration of vismodegib (>20 µM) was required to suppress the growth of 
IL45 and IL45-luc cells. This concentration is in the range reported for most human cancer cell lines 
having ligand dependent activation as well as human MPM cells (IC50 = 15-20 μM) (7, 27). 
Nevertheless, the concentration used in these studies was far higher than the effective concentration 
(100-500 nM) of vismodegib required to completely inhibit Hh pathway activity of responsive cell lines 
(13, 27). In the contrast to these studies, we could not observe a significant reduction of Gli1 
expression after exposing IL45 cells to various concentrations of vismodegib. Similarly, a study in 
various other cancer cell lines showed that the treatment with Hh antagonist as well as ligand blocking 
antibody did not induce down regulation of GLI1, the well-described Hh target gene in vitro (13). Thus, 
it is still a matter of debate whether the growth inhibitory effect of SMO antagonist observed in vitro is 
only due to off-target effects when applied at high concentration. Vismodegib was shown to inhibit 
ABCG2 drug transporter (35) as well as cellular calcium homeostasis (36) when applied at a high 
concentration. Thus, the lack of Gli1 downregulation after treatment with vismodegib in vitro suggested 
that the growth inhibitory effect observed herein may result from off target effects. Nonetheless, given 
the heterogeneic nature of MPM, the effect may depend on the cell lines employed. Indeed, Shi et al 
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(5) described that only 4 out of 6 cell lines cultured in 3%O2 without serum showed down-regulation of 
Gli1 in response to SMO antagonist treatment.    
GLI1 has been shown to be activated in Hh independent fashion, via cross-talking with other 
oncogenic pathways such as KRAS, EGFR and mTOR (8, 37). A recent study demonstrated that GLI1 
was highly expressed in some MPM tumors of which SHH expression was absent (7), suggesting a 
possible role of GLI1 activation in Hh signaling independent manner (13). A recent study suggests a 
better proliferation inhibitory effect of GLI1 inhibitor (GANT61) compared to vismodegib on MPM cells 
(7). Nevertheless, the role of non-canonical ligand dependent Hh activation in MPM has to be explored 
in more detail. Besides, agents targeting GLI1 have not yet been available for clinical use.  
We have the advantage of using an immunocompetent pre-clinical model that contains 
clinically relevant stromal components including extracellular matrix, fibroblasts and immune cells. 
However, there are limitations of our study including short treatment and observation period; the major 
reason for this limitation being the aggressiveness of the model that influences animal well-being. 
Vismodegib was shown to inhibit the drug transporter, ABCG2 with the IC50 of more than 1 µM (35). 
ABCG2 was important for the efflux of Bli substrate luciferin, thus the treatment with vismodegib 
caused false positive Bli signal (38). We indeed observed the effect of vismodegib in interfering 
luciferin efflux in IL45-luc at concentration of > 1 µM in vitro, (sustained Bli decline rate, supplementary 
figure s5). A large proportion of circulating vismodegib (98% in rats (39)) is bound to serum alpha 1-
acid glycoprotein (AAG). An in vivo study in mice receiving 100 mg/kg demonstrated a Cmax of 35 µM 
for total vismodegib (22). Thus we estimate to have approximately 0.7 μM of unbound vismodegib in 
the rat serum. This concentration still does not interfere with Bli. Moreover, persisting Bli signal should 
be observed when ABCG2 was inhibited (38), but Bli kinetics after the substrate administration in 
control and treated animals are similar (supplementary figure s5). These data ruled out the possible 
interference of vismodegib on the detection of tumor by Bli in this study. 
Here, we employed an immunocompetent preclinical model of MPM to demonstrate that the 
Hh pathway inhibition in MPM affects the production of extracellular matrix and cytokines, factors 
crucial for tumor progression. Our study also provides novel information regarding the role of Hh 
signaling in MPM in stroma.  
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Figure legends 
Figure 1. Analysis of Hh pathway activation in human MPM specimens and rat MPM model in 
tumor and stromal fractions. a) Immunohistochemical detection of GLI1, DHH, PTCH1 and HHIP in 
tumor (T) and stroma (S) and box  plot of semi-quantitative expression levels (H-score) of GLI1 and 
DHH in146 MPM specimens, and PTCH1 and HHIP in 8 MPM specimens (lines indicate medians). b) 
Histology of rat MPM model revealed cellular areas of closely packed spindled tumor cells (T) with 
relatively large, irregular nuclei, adjacent to stroma (S) containing fibroblasts (organized small spindle 
cells, *), blood vessels (X) and inflammatory cells (small round cells with dense blue chromatin; arrow). 
Of note is the presence of some fibroblasts and inflammatory cells also in the tumor area. Scatter plot 
shows semi-quantitative expression levels of GLI1, DHH, PTCH1 and HHIP (H-score) of 6 tumors 
(lines indicate medians).  
Figure 2. The comparison of Hh pathway activation in vitro and in vivo rat MPM model. 
a) Expression levels (mRNA) of pathway components  were monitored in IL45-luc cultured in 10% 
serum, primary cell culture in 3% O2 without serum compared to tumor from the rat model (in vivo). b) 
Cell growth measurement by MTT (left) and colony formation assay (right) shows that IL45-luc and the 
parental line (IL45) cultured in 20%O2 with serum are identically sensitive to vismodegib (Data are 
given in mean + SD; *, p<0.05; **, p<0.001; ***, p<0.0001). c, d) IL45 parental cells were exposed to 
increasing concentration of vismodegib and measured for the down regulation of hedgehog pathway 
target gene (Gli1 and Ptch1) in addition to Gli2 and Gli3. No significant suppression of all genes was 
observed upon the treatment course (24 and 48 hours).  
Figure 3. Daily treatment with vismodegib effectively reduces tumor volume and growth in vivo. 
a) Experimental scheme of orthotopic rat MPM model and the treatment with vismodegib. b) Box and 
whisker plot of tumor volume quantified from MRI images performed at the last day of treatment 
(representative images are shown in (c). d) Macroscopic tumor volume performed at the last day of 
treatment. e) Tumor growth monitored by bioluminescence (total flux) over a period of 6 days and 
representative images. (Data are given in mean + SD; *, p<0.05; **; p<0.001; ***; p<0.0001) 
Figure 4. Efficient down regulation of Hh signaling and reduce tumor cell growth following the 
treatment with vismodegib. a) mRNA levels of Hh target genes, Gli1 is strongly reduce in skin and 
tumor of vismodegib treated rats. Expression level of other GLI1 target genes, Ptch1 and Hhip is also 
reduced in treated tumor compared to control. Dhh, Gli2, Gli3 expression remains unchanged. b) 
Immunohistochemical staining of GLI1 and HHIP showing reduced expression (intensity and 
on May 9, 2016. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 2, 2016; DOI: 10.1158/1535-7163.MCT-15-0583 
19 
 
                                                                Vismodegib reduces mesothelioma growth by affecting stroma  
frequency) in treated compared to control. More GLI1, HHIP negative stromal cells are present in the 
treated rat (see circles T:tumor, S:stroma). c) Quantitative analysis histo(H)-score of GLI1, HHIP, 
PTCH1 and DHH staining showing pronounced GLI1 and HHIP downregulation in stromal fractions. d) 
Proliferation (Ki-67 positive), mitotic (phospho-histone H3 positive) indices are significantly reduced in 
the treated group. No change in necrosis and apoptosis level (TUNEL positive nuclei) is observed 
between groups. (C: Control; n=6, T: Treated; n=6, Data are given in mean + SD; *, p<0.05; **; 
p<0.001; ***; p<0.0001) 
Figure 5. Vismodegib dose-dependently suppresses growth of mesothelioma cells but could 
not suppress Hh pathway in vitro.  
a) Primary cells isolated from 4 different rat tumors cultured in 3% O2 without serum and IL45-luc cell 
line cultured 20%O2 were exposed to increasing concentration of vismodegib and measured for 
viability. No difference in terms of sensitivity to vismodegib was observed (Data are given in mean + 
SD). b) Two lines of primary cell (isolated from control rats) were treated with vismodegib for 24 hours 
and analyzed for the down regulation of Gli1. No significant suppression of Gli1 was observed. c) IC50 
of vismodegib determined in 4 cell lines after 72 hour treatment (MTT assay) d) the expression levels 
of Hh pathway components (Dhh, Smo, Ptch1, Gli1) of the 4 cell lines showing no correlation with their 
sensitivity to vismodegib  
Figure 6. Daily treatment with vismodegib  causes down regulation of previously described 
fibroblast Hh responsive genes. a) mRNA levels of canonical Hh target gene such as CyclinD1, 
Abcg2 remained unchanged in vismodegib treated group compared to control. Previously described 
fibroblast Hh responsive genes i.e. Fibronectin, Vegf and Lif mRNA levels were reduced in vismodegib 
treated group. (C: Control; n=6, T: Treated; n=6, Data are given in mean + SD; *, p<0.05; **; p<0.001; 
***; p<0.0001) b) Mouse embryonic fibroblast NIH3T3 cells were treated with supernatant collected 
from primary culture of rat MPM cells. Treatment with SMO agonist (SAG) was employed as a positive 
control. Gli1, Ptch1 and Fn1 expression levels were analyzed after 72 hours incubation at 37 °C 3%O2 
(data represent mean of triplicates +  SD) 
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